Hepatology

期刊全称

Hepatology

期刊缩写

HEPATOLOGY

涉及主题

医学生物内科学遗传学化学生物化学胃肠病学免疫学病理内分泌学外科病毒学基因

期刊介绍

The premier publication in the field of liver disease publishes original, peer-reviewed articles concerning all aspects of liver structure, function and disease. Each month, the distinguished editorial board monitors and selects only the best articles on subjects such as immunology, chronic hepatitis, viral hepatitis, cirrhosis, genetic and metabolic liver diseases and their complications, liver cancer, and drug metabolism.

期刊ISSN

print: 0270-9139 on-line: 1527-3350

历年影响因子

2025年	2024年	2023年	2022年	2021年	2020年	2019年	2018年
15.8	12.9	13.5	17.298	17.425	14.679	14.971	14.079

历年发表/被引量

年份	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
发表量	176	448	509	527	568	613	646	646	646	736	671	717
被引量	91	1966	5606	22915	15699	22994	32143	35459	45695	61297	42578	59597

h-Index

326

自引率

4.70%

涉及的研究领域

医学-胃肠肝病学

2026年新锐分区

大类	小类	TOP期刊	综述期刊
1区	1区胃肠肝病学	是	N/A

中科院2025年分区

大类	小类	TOP期刊	综述期刊
1区	1区胃肠肝病学	是	否

WOS期刊分区

JCR学科分类

JCR分区学科名称	收录数据库	JCR分区	分区排名
GASTROENTEROLOGY & HEPATOLOGY	SCIE	Q1	7/153

JCI学科分类

JCI分区学科名称	收录数据库	JCI分区	分区排名
GASTROENTEROLOGY & HEPATOLOGY	SCIE	Q1	7/153

期刊主页

http://aasldpubs.onlinelibrary.wiley.com/hub/journal/10.1002/(ISSN)1527-3350/https://journals.lww.com/hep/Pages/default.aspx

投稿网址

http://mc.manuscriptcentral.com/hep

出版商

John Wiley and Sons Ltd

出版国家（地区）

UNITED STATES

出版语言

English

出版周期

Monthly

每年出版文章数

459

Gold OA文章占比

20.38%

原创研究文献占比
(排除综述)

85.02%

SCI收录类型

Science Citation Index Expanded (SCIE)

Scopus (CiteScore)

PubMed链接

http://www.ncbi.nlm.nih.gov/nlmcatalog?term=0270-9139%5BISSN%5D

平均审稿周期

平均1.0个月

平均录用比例

约37.5%

Hepatology

JCR学科分类

JCI学科分类

期刊相关文献 (3213)

Deep learning-assisted tumor radiomic dynamics on MRI predict pathological complete response in HCC undergoing immune-based therapy followed by hepatectomy

基于深度学习的肿瘤放射组学动态分析预测接受免疫治疗后行肝切除术的肝细胞癌患者的病理完全缓解

Parallel regulation of goblet cell-associated antigen passages by reduced microbial sensing and mAChR4 signaling in Muc2 deficiency prevents ethanol-induced liver injury

Muc2缺陷导致微生物感知和mAChR4信号传导减弱，进而平行调控杯状细胞相关抗原的转运，从而预防乙醇引起的肝损伤。

Locoregional lactate dehydrogenase inhibition potentiates therapy and overcomes treatment resistance in hepatocellular carcinoma

局部乳酸脱氢酶抑制可增强肝细胞癌的治疗效果并克服治疗耐药性。

Repurposing Resmetirom suppresses MASH-associated hepatocellular carcinoma, with mechanistic implications of MDK/LRP1-mediated metabolic reprogramming and immunosuppression

重新利用Resmetirom可抑制MASH相关肝细胞癌，其机制涉及MDK/LRP1介导的代谢重编程和免疫抑制。

Evolving precision: Updates in targeted therapy for cholangiocarcinoma

精准治疗的不断演进：胆管癌靶向治疗的最新进展

Pruritus is common in primary sclerosing cholangitis, persists over time, and its intensity is associated with disease severity: a multicentre, prospective observational study

原发性硬化性胆管炎患者常出现瘙痒，且瘙痒持续时间较长，其严重程度与疾病严重程度相关：一项多中心前瞻性观察研究

Multiomics combined with machine learning defines unique molecular subtypes of cholangiocarcinoma and identifies TNK1 as a therapeutic target

多组学结合机器学习技术定义了胆管癌独特的分子亚型，并将TNK1确定为治疗靶点。

Non-transcriptional activity of IRF3 promotes liver fibrosis and stress granule assembly via a dsRNA-TLR3-dependent pathway in hepatic stellate cells

IRF3的非转录活性通过肝星状细胞中dsRNA-TLR3依赖性通路促进肝纤维化和应激颗粒组装。

Epigenetic repression of hepatocyte FoxO1 disrupts local immune homeostasis and promotes liver inflammation

肝细胞FoxO1的表观遗传抑制会破坏局部免疫稳态并促进肝脏炎症。

Anti-angiogenic therapy combined with immune checkpoint blockade mediates CCR7 + CD8 + T-cell entry into HCC through high endothelial venules

抗血管生成疗法联合免疫检查点阻断介导CCR7+CD8+T细胞通过高内皮静脉进入肝细胞癌